|

Toripalimab and axitinib Clinical Trials

1 actively recruiting trial

Also known as: Super-selective tumor arterial embolization

Pipeline

Phase 2: 1

Top Sponsors

  • Tianjin Medical University Second Hospital1

Indications

  • Renal Cell Carcinoma (RCC)1
  • Cancer1

Other1 trial

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.